 |
Inside Startup Investing with Chris LustrinoAuthor: Kingscrowd, Sam Fiske
Join Chris Lustrino as he talks to startup founders, angel investors, fund managers, investing platform executives, and more about the online private markets. Inside Startup Investing gives listeners the inside scoop on alternative investing such as startups from an investor and founder perspectives. Language: en-us Genres: Business, Investing, Technology Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
How Sen-Jam Is Building a Portfolio of Inflammation Drugs
Episode 168
Thursday, 26 March, 2026
In this episode of Inside Startup Investing, Chris Lustrino speaks with Jim Iversen, CEO of Sen-Jam Pharmaceutical, about building a platform of therapeutics targeting inflammation across multiple diseases. (00:00–01:28) The company is advancing a pipeline of drugs addressing conditions like COVID, alcohol-related inflammation, and arthritis, with multiple Phase 2 trials completed. (01:28–02:27) Jim explains how drug development works—from preclinical research to Phase 1 (safety), Phase 2 (efficacy), and Phase 3 (confirmatory trials). (04:14–06:05) They explore how Sen-Jam uses AI and over one million data points to validate its platform and identify new drug opportunities. (08:32–09:30) The discussion also covers how the company allocates resources across its pipeline and its strategy to license drugs after Phase 2 rather than fully commercialize them. (13:10–14:32) Finally, Jim breaks down the economics of drug licensing, potential valuation inflection points, and how investors can think about returns in biotech. (19:31–21:58)
